⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Juno Pharma Canada Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Juno Pharma Canada Inc.
↗Montreal, Canada
Juno Pharma Canada Inc. is a specialty pharmaceutical company focused on the development, production, marketing, and distribution of high-quality, cost-effective injectable and non-injectable medications. The company serves the Canadian healthcare market with a strong emphasis on hospital-based products, including sterile injectables, allergy extracts, and specialized phlebology treatments.
Following the 2025 merger of Juno Pharmaceuticals Corp. and Omega Laboratories Limited, the company has significantly expanded its domestic manufacturing capabilities. Juno is committed to addressing drug shortages and improving supply chain resilience for critical medications in the Canadian healthcare system.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Injectables
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:HollisterStier (Exclusive Canadian distributor for allergy product line), Conavi Medical (Investment partner)
COMPETITION
Position:Challenger
Competitors:Mayne Pharma, Omega Laboratories (Merged)
LEADERSHIP
Key Executives:
Mark Mantel - CEO
LINKS
Website:junopharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Juno Pharma Canada Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.